• I am dual-trained in both Medical Hematology/Oncology and Clinical Pharmacology and Pharmacogenomics at the University of Chicago. My specialty training allowed me to develop expertise in clinical trial design, pharmacokinetics (PK)/pharmacodynamics (PD) analysis, drug development, and patient care. In September 2015, I joined the faculty at the University of Alabama at Birmingham as an Assistant Professor of Medicine. My focus remains in highly aggressive women’s malignancies (i.e. triple-negative and HER2+ breast cancer as well as high-grade serous ovarian cancer) and early-phase clinical trial design. In this role, I serve as a clinician-scientist helping laboratory-based scientist translate laboratory findings to the clinical setting by designing trials.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Association of Event-Free and Distant Recurrence-Free Survival with Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical TrialJAMA Oncology.  6:1355-1362. 2020
    2020 Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialJAMA Oncology.  6:676-684. 2020
    2020 Breast cancer, version 3.2020 2020
    2020 MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative breast cancers in the I-SPY 2 trialJournal of Clinical Oncology.  38:1059-1069. 2020
    2019 Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology.  5:1141-1149. 2019
    2018 Future Developments in Neoadjuvant Therapy for Triple-Negative Breast CancerSurgical Clinics of North America.  98:773-785. 2018
    2017 MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancerBreast Cancer Research.  19. 2017
    2016 A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancerSpringerPlus.  5. 2016
    2015 Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinomaGynecologic Oncology.  138:656-662. 2015


    Year Title Altmetric
    2014 Chemotherapy and/or targeted therapies for advanced endometrial cancer: Time to rethink?.  59-68. 2014

    Research Overview

  • Breast Cancer
    Ovarian Cancer
    Developmental Therapeutics
    Translational Research
  • Education And Training

  • Doctor of Medicine, University of South Alabama 2008
  • Bachelor of Science or Mathematics in Biomedical Sciences, Auburn University 2004
  • Tulane University, Internship 2009
  • Baptist Health System, Residency 2011
  • University of Chicago, Postdoctoral Fellowship 2015
  • University of Chicago, Postdoctoral Fellowship 2014
  • Full Name

  • Erica Stringer-Reasor